Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Elite Clinical Studies

Neither a doctor nor a teaching hospital

Research payments

$2,761,700

204 payments

Through program year 2025, Elite Clinical Studies is reported as receiving $2,761,700 in research payments, across 204 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $150,975 6
2024 Research $1,305,768 47
2023 Research $351,592 16
2022 Research $21,602 3
2021 Research $129,461 33
2020 Research $327,488 50
2019 Research $474,814 49

Breakdown

Who paid Research payments · program years 2019–2025
  1. Braintree Laboratories, Inc. $950,788 28 payments
  2. Incyte Corporation $636,872 65 payments
  3. Novartis Pharmaceuticals Corporation $623,895 19 payments
  4. AstraZeneca Pharmaceuticals LP $220,256 10 payments
  5. E.R. Squibb & Sons, L.L.C. $197,532 10 payments
  6. Teva Pharmaceuticals USA, Inc. $44,284 23 payments
  7. AbbVie, Inc. $34,968 25 payments
  8. Sun Pharmaceutical Industries Inc. $21,753 9 payments
  9. Taro Pharmaceuticals USA, Inc. $17,382 4 payments
  10. GlaxoSmithKline, LLC. $6,350 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis $950,788 28 payments
  2. TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $354,972 33 payments
  3. A 5-Year, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Assessing the Efficacy, Safety, and Tolerability of Intra-Articular Regimens of Lna043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis $332,643 3 payments
  4. TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $281,900 32 payments
  5. A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy $186,277 4 payments
  6. a randomised,double blind,placebo controlled study to evaluate cortisol reserve in response to adrenocorticotropic hormone stimulation test following treatment with baxdrostat for eight weeks in participants with ucontrolled hypertension $98,581 3 payments
  7. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $79,540 8 payments
  8. A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma $73,570 2 payments
  9. Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of BMS-986165 in Participants with Systemic Lupus Erythematosus $67,202 2 payments
  10. Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of BMS-986165 in Participants with Systemic Lupus Erythematosus $50,205 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record